Published today in Current Biology, a study by Sofia J.
Latest news
News
27 Sep 2016
IRB Barcelona’s Innovation Office will be in Bilbao from 28 to 30 September to participate in BioSpain, the main biotech gathering in southern Europe and the fifth-ranked event worldwide on the bas
22 Sep 2016
Today, Jelena Urosevic and Carles Barceló, postdoctoral fellows at the Institute for Research in Biomedicine (IRB Barcelona), will officially be presented with funding over 5 years
20 Sep 2016
Changes in body organ morphology have allowed animals to better exploit diverse habitats.
Media mentions
25 Sep 2016
Salvador Aznar-Benitah: “Do things you are passionate about, not what is convenient”
La Vanguardia
This week, Big Vang, published by La Vanguardia, devotes its interview to ICREA researcher at IRB Barcelona, Salvador Aznar-Benitah, head of the Stem Cell and Cancer Lab.
20 Sep 2016
Roger Gomis: "Tumours are in continuously evolving"
Diari Ara
The newspaper ARA publishes an hard copy and digital interview with the ICREA researcher Roger Gomis, who is specialised in cancer metastasis, especially of the breast.
16 Sep 2016
Joan Guinovart on morning chat show Els Matins de TV3
TV3 - Els Matins
As of this September and on alternate Fridays, the director of IRB Barcelona, Joan Guinovart, is to be one of the invited guests on the chat show El Matins de TV3, which is presented by Lídia Heredia.
Felice Alessio Bava
former PhD student in the Translational Control of Cell Cycle and Differentiation Lab
«We suspected that CPEB1, a protein involved in regulating mRNA translation in the cytoplasm, might also be active in the nucleus and play a role in controlling pre-mRNA processing. We discovered that it affects the alternative generation in the mature mRNA of the 3'-UTR, regions where most of the elements regulating translation in time and space are located.»
More info about this news here.
Jalaj Gupta
Postdoctoral Fellow
«Our study highlights the complexity of p38 functions, both in cancer and in the maintenance of normal tissues. It shows why an inhibitor of this molecule could effectively have undesirable side effects. But these do not exclude it from being a target against cancer.»
More on this news here.
Meritxell Teixidó
Research Associate
«98% of the potential therapeutic molecules against diseases of the central nervous system cannot cross the blood-brain barrier. We develop peptides with the capacity to open the doors of the barrier and act as shuttles when attached to a therapeutic molecule.»
Laura Boulan
PhD Student
«I discovered that the bantam molecule drives the transition from larva to pupa, the phase analogous to human adolescence.»
More info about this news here.
Laura Nevola
Research Associate
«Controlling a biological process from outside is the future of chemistry and opens up promising roads for advancements in pharmacological research.»
More info on this news here.
Eduard Batlle
Group Leader
Group: Colorectal cancer laboratory
«We need to look at the soil, not at the seed. TGF-beta is the fertiliser that changes the earth in which the tumour seed grows.»
More info about this news here.
Lara Barrio
Postdoctoral Fellow
“From our study in Drosophila flies we can deduce that it would be particularly interesting to address vertebrates and analyse the participation of p53 in diabetes and obesity”
More on this news here
Photo gallery
New strategy to obtain a specific type of amyloid-beta aggregate that may underlie neuronal death in Alzheimer’s disease
New strategy to obtain a specific type of amyloid-beta aggregate that may underlie neuronal death in Alzheimer’s disease
Two proteins safeguard skin stem cells
Researchers discover the machinery that neurons use to form and maintain their neuronal extensions
The absence of a single protein spurs muscle aging in mice
Discovery of molecular protection linked to a degenerative neuromuscular disease
Discovery of a fundamental limit to the evolution of the genetic code
Researchers discover that breast cancer tumour growth is dependent on lipid availability
Researchers discover that breast cancer tumour growth is dependent on lipid availability
Researchers discover that breast cancer tumour growth is dependent on lipid availability
Contact
Quick facts about IRB
Quick facts
IRB Barcelona has been awarded the "HR Excellence in Research" logo. This recognition reflects the commitment of the Institute to continuously improving its human resources policies in line with the European Charter for Researchers and the Code of Conduct for the Recruitment of Researchers. The award confirms the efforts of the Institute to ensure fair and transparent recruitment and appraisal procedures. Click here for more information.
IRB Barcelona is home to nearly 450 research, technical and support staff from 35 countries who share the common goal of contributing to the advancement of the biomedical sciences through investigator–driven research, and improving quality of life by applying advances in this field.
The convergence of biology, chemistry, and structural and computational biology is unique at IRB Barcelona and opens a strategic window to gain insight into basic molecular processes in health and disease.
Research is conducted by 23 groups organized into 5 interdisciplinary programmes. Each programme includes a diverse faculty of researchers with overlapping scientific interests. The research areas have been structured to be highly interactive, fostering multidisciplinarity by combining modern molecular biology, classical genetics, biochemistry, structural biology, bioinformatics, systems biology, advanced microscopy, and genomic and proteomic approaches.
Our Board of Trustees comprises members of the Catalan Government (from the Department of Economy and Competitivity and the Department of Health), the University of Barcelona, a representative from the BBVA Foundation as well as internationally renowned scientists.